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CHAPTER 1 INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most acute malignant blood disease affecting
children. This disease represents about 80% of acute types of leukemia and the most common
cause for children’s death under twenty years of age [1]. It was estimated that in the United States,
2500-3500 new pediatric patients were diagnosed with ALL yearly with an incidence rate of 3.4
in 100,000 cases [2]. In Northern America, the incidence rates of ALL among male children are
more than 10 in 100,000 and among female children are more than 7 in 100,000 [3]. This type of
leukemia is characterized by a malignant proliferation and mutation of immature lymphoid cells
residing in the blood, bone marrow, and other organs. Although most of the cases are de novo ALL
in a formerly healthy pediatric population, a small number of cases are attributable to predisposing
factors including genetic syndromes such as Down syndrome, ataxia-telangiectasia, Fanconi
anemia, exposure to some viruses such as HIV and EBV, and ionizing radiation. ALL in pediatric
patients develop in the T & B lymphoblasts of the bone marrow [4]. Pediatric ALL patients
experience signs of bone marrow failure such as thrombocytopenia, anemia, and leukopenia, in
addition to some agonizing symptoms such as pain, fever, fatigue, bleeding, and bruising. ALL is
diagnosed when at least 20% lymphoblasts are detected in bone marrow or peripheral blood [4].
Aggressive chemotherapy regimens commonly used in the treatment of pediatric patients with
ALL manifest high response rates; however, they contribute to a variety of complications and
adverse events.
CHAPTER 2 LITERATURE REVIEW
The incidence of ALL has increased in the United States and globally. This increase is
attributed to the advancement in diagnostic techniques and improved access to health care. The
stages of ALL can be identified by examining the B and T cells for chromosomal or genetic
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variations and classified into abnormalities such as hypodiploidy and hyper-diploidy,
amplification, a translocation between different chromosomes, and other unspecified
abnormalities. Prognostic predictors of ALL depend on using risk-based stratification and the
response to the initial therapy [1]. When prognostication of ALL is accomplished, patients can be
assigned to different treatment protocols. Incremental advances in treatment protocols have led to
the survival of approximately 80% of the pediatric cases with 5-year event-free survival [5].
However, ALL survivors have to be closely monitored for risks and complications associated with
ALL treatment.
Risk Stratification for Newly Diagnosed ALL Patients
The paradigm of pediatric ALL treatment depends mainly on risk-based stratification at
initial diagnosis. Based on the patient’s features impacting prognosis and risk of therapy failure,
cases can be categorized to receive different treatment regimens. High-risk cases usually receive
more aggressive and toxic treatment than standard risk cases. Also, the categorization of children
with ALL is influenced by another set of risk criteria including age and leukocytes, referred to as
the National Cancer Institute (NCI) criteria. Infants and children older than ten years are prone to
higher risks of the disease than those children between the ages of 1-10 years old who are at
standard risk. Higher levels of leukocytes (>50,000/µL) contribute to greater risk in infants and
children older than ten years, while children between the ages of 1-10 years old with lower levels
of leukocytes (<50,000/ µL) are considered at standard risk [1].
Another high-risk factor at initial diagnosis is the involvement of the sanctuary sites, which
are extramedullary anatomic locations that resist the penetration of systemic chemotherapy and
prevent it from reaching the leukemia cells. At diagnosis, studies show that nearly 3% of pediatric
patients are likely to display CNS disease interpreted as diagnostic lumbar puncture associated
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with the existence of more than five leukocytes/µL and leukemic blasts on cytospin or the presence
of other CNS diseases such as the cranial nerve palsy [1]. Moreover, an initial diagnosis in nearly
2% of boys will demonstrate testicular involvement such as enlarged, nonpainful testes.
Furthermore, the patients will be at higher risk if they have used corticosteroids before being
diagnosed with ALL as this might diminish the number of leukocytes and the presence of sanctuary
sites [6].
The features of leukemia cells (B versus T lymphocytes) that affect prognosis can be
described through the immunophenotype and be used as a sign for differentiating those patients
who are at higher risk. Around 80% of pediatric ALL patients have B-precursor immunophenotype
which poses a lower risk on those patients [6]. However, ALL patients with T-cell
immunophenotype have poor survival rates unless they have received more intensive treatment to
increase their cure rate [1]. Those pediatric patients who have early T-precursor (ETP) ALL were
found in some studies to be less likely to survive. Furthermore, under 5% of pediatric acute
leukemias experience immunophenotypic groups of mixed lineages that cannot be identified as
lymphoid or myeloid in origin or experience double lineages that include both lymphoid and
myeloid and/or B and T cells origins [6]. These obscure immunophenotypes are linked to
unfavorable prognosis [1, 7].
In addition, a molecular classification of risk associated with some markers is recognized
with recurrent cytogenetic abnormalities with favorable or unfavorable prognosis. High hyperdiploidy and ETV6/RUNX1 fusion are the most favorable cytogenetic aberrations. It is wellestablished that in about 30% of B ALL pediatric cases there exist high hyper-diploidy defined as
51–65 chromosomes or DNA index (≥ 1.16) [6, 7]. Children with high hyper-diploidy are likely
to have a favorable prognosis and outcome with trisomies of chromosomes 4 & 10. In the same

4
manner, a favorable prognosis is experienced with about 25% of B ALL cases in children who
carry the cytogenetic aberration: ETV6/RUNX1 fusion (due to t [12;21], formerly TEL/AML1)
[6, 7]. Except for these two types, other cytogenetic aberrations do not yield any favorable
prognosis. One example is hypodiploidy which is characterized by less than 44 chromosomes or
DNA index (< 0.81) is related to unfavorable prognosis and outcome [6, 7].
Another example of unfavorable prognosis and outcome is the abnormality of MLL gene
rearrangements found in chromosome 11q23. MLL gene rearrangements are noticed in 80% of
infants with ALL and 5% of ALL children from age 1-18 years [1]. Because MLL gene
rearrangements in infants with ALL are too aggressive, these infants receive more intensive
cytotoxic treatment than older children [7]. Furthermore, Philadelphia chromosome-positive (Ph+)
ALL observed with BCR-ABL fusion of t (9;22) is another abnormality that results in unfavored
prognosis with standard chemotherapy and is observed in 3% of childhood ALL [6]. Philadelphia
chromosome-positive (Ph+) ALL leads to high MRD levels, early relapse, and its treatment
outcomes are usually poor [8]. Therefore, patients with (Ph+) ALL are given other alternative
therapies such as hematopoietic stem cell transplant and kinase-targeted therapy [7, 8]. A study by
Dai et al. confirmed the effectiveness of using the tyrosine kinase inhibitor dasatinib in the
treatment of Philadelphia chromosome-positive (Ph+) ALL [8].
Risk Associated with Response to Initial Therapy for ALL Patients
In addition to previous risk factors associated with prognosis, another strong prognosis
predictor is the reaction to the initial therapy. Commonly, a large number of children with ALL
attain complete remission with less than 5% lymphoblasts on microscopic morphology at the end
of the induction phase. However, induction failure with more than 5% lymphoblasts is noticed in
about 2% of pediatric patients with ALL indicating an unfavorable prognosis with a 33% survival
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rate [6]. Induction failure is observed among patients experiencing MLL rearrangement, T-cell
immunophenotype, B-precursor immunophenotype (Bp) with high numbers of leukocytes, and
Philadelphia chromosome, or observed in older age children [9].
Microscopy examination is challenging, especially in the evaluation of bone marrow and
that is why it was replaced with evaluating minimal residual disease (MRD). Evaluating MRD is
attained by using flow cytometry or polymerase chain reaction (PCR) that allows detection of
leukemic blasts up to 1 in 10,000 – 100,000 cells [10]. The evaluation of MRD is a very powerful
means for identifying the patient’s response to early treatment. It is an independent factor for
predicting outcome in pediatric patients with ALL, proved to be effective in the peripheral blood
as early as day 8 of therapy, and an indication of the level of intensity needed in treatment regimens
[7, 10]. Moreover, the risk for relapse is associated with MRD levels at the end of induction of 45 weeks and the end of consolidation of 10-12 weeks [7]. Currently, end-induction MRD is
normally used for pediatric patients with Bp ALL in risk stratification. However, using MRD for
T-cell ALL treatment regimen is developing and hopefully promising. These risk factors are
implemented by various oncology groups for pediatric patients, such as the Children’s Oncology
Group (COG) and the Berlin-Franklin-Münster (BFM) Group [10].
Treatment of Newly Diagnosed ALL Patients
When it comes to the treatment of newly diagnosed patients, it is significant to prevent
incidences of resistance by using four groups of treatment based on multi-drug regimens. There is
a variety of chemotherapy regimens with different intensity levels depending on the child at risk.
There are four main phases of ALL treatment that include the remission induction, consolidation,
maintenance, and therapy directed to the central nervous system (CNS), in addition to the
allogeneic hematopoietic stem cell transplant (HSCT) as illustrated in table 1. The phases of
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pediatric ALL treatment usually take 2-3 years. The more aggressive the disease, the more
intensive is the chemotherapy regimen [11].
The first stage of chemotherapy is 4-6 weeks of remission induction. The initial treatment
and regimen are established in the hospital until complications subside allowing the patient to be
discharged and will receive outpatient follow-up. The first stage is aimed to complete remission
induction which sets a benchmark to about 95% of all pediatric patients upon completion [6].
Those patients who fail to receive complete remission by the end of induction are prone to either
induction failure or surrender to treatment-related mortality. The patients who do not achieve
remission and experience induction chemotherapy failure are subjected to allogeneic bone marrow
transplant. Drugs used for induction chemotherapy include corticosteroids, vincristine, and
asparaginase [11]. Moreover, a great number of therapy regimens use anthracyclines such as
doxorubicin or daunorubicin in addition to the previously mentioned drugs. Doxorubicin and
daunorubicin were found to have the same efficacy and toxicity in randomized trials. Therefore,
some therapy groups do not use these anthracyclines with lower-risk groups to avoid their toxicity
and further complications [1].
The two types of corticosteroids commonly used in chemotherapy are prednisolone and
dexamethasone. While dexamethasone shows improvement in central nervous system penetration
and reduced risk of relapse, it maximizes the occurrence of toxicity leading to infection, reduction
in linear growth, and avascular necrosis [12]. Several forms of L-asparaginase are currently used
for the pediatric treatment of ALL for asparagine depletion. These forms include Pegaspargase
(PEG-asparaginase), asparaginase Erwinia chrysanthemi (Erwinia L-asparaginase), and
native Escherichia coli (E. coli) L-asparaginase. The native Escherichia coli (E. coli) Lasparaginase is not used in the United States. L-asparaginase agents are the cornerstone of ALL
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treatment regimens in children and these agents adequately improve event-free survival (EFS)
[13]. The covalent attachment of polyethylene glycol has been used to modify the E. coli enzyme
in Pegaspargase. Pegaspargase is the most common type used both intramuscularly (IM) and
intravenously (IV) for both induction and postinduction stages of treatment in children newly
diagnosed with ALL. A single dose of Pegaspargase injected for the first time, as part of an
induction multiagent regimen, leads to a serum asparaginase enzyme activity level that exceeds
100 IU/L and is associated with prolonged asparagine depletion [14]. As for Erwinia Lasparaginase, it is normally used with children who are allergic to Pegaspargase. Due to the shorter
half-life of Erwinia L-asparaginase, it should be frequently administered to allow asparagine
depletion [15].
The second phase of chemotherapy that follows remission induction is consolidation.
Consolidation is meant to eliminate the submicroscopic residual disease that exists after complete
remission. The phase of consolidation lasts from 6-9 months based on the protocol used and level
of risk. Whereas this phase of chemotherapy is administered mainly in outpatient care, a more
aggressive regimen can be required using inpatient care. For children with ALL who are at higher
risk, the consolidation phase is more intense and lasts for a longer period of time. Several
chemotherapeutic agents such as cyclophosphamide, cytarabine, thioguanine, methotrexate,
etoposide, and one of the thiopurine drugs such as mercaptopurine are integrated and administered
in the consolidation phase. These agents are mainly used to increase synergy and reduce drug
resistance in the consolidation phase, and they are often not part of the initial induction phase [6].
The third stage of therapeutic treatment in pediatric ALL is the maintenance chemotherapy
phase. This phase is the last and longest stage of treatment that lasts approximately two years.
However, boys need longer treatment that reaches three years. Maintenance chemotherapy is less
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intensive, is associated with less disruptive toxicity, and aims toward minimizing the risk of
relapse. This phase is an antimetabolite therapy involving drugs such as methotrexate and 6mercaptopurine as a thiopurine drug which can be administered orally through outpatient care [16].
Several randomized studies demonstrated that longer periods of maintenance therapy are
associated with a reduced risk of relapse. However, elevated risk of developing second cancers has
been associated with longer periods of maintenance therapy and higher doses of both methotrexate
and 6-mercaptopurine [17]. Furthermore, reducing maintenance therapy duration to less than two
years was found to lower the event-free survival possibility. To acquire the cytotoxic effect of the
6-Mercaptopurine drug, metabolic activation is necessary. The activity of this drug is utilized by
its transformation into thioguanine nucleotides (TGN) and its incorporation into the DNA of
multiplying cells, thus elevating the levels of DNA-TGN. The DNA-TGN is the endpoint
metabolite of 6-mercaptopurine and is responsible for its cytotoxic effect and its short-term and
long-term adverse events. These adverse events include fatal myelosuppression and second
malignant neoplasia [18]. There is evidence from studies that the risk of relapse is associated with
the degree of myelosuppression. Therefore, several regimens provide instructions for dose change
to balance the risk of myelosuppression with the risk of severe pancytopenia. Moreover, other
regimens use vincristine and steroids too [16].
A very crucial component of pediatric ALL treatment is the therapy against the CNS
disease, whether it is detected at diagnosis or developed during the course of ALL disease. This
therapy includes integration between chemotherapy and other drugs for CNS prophylaxis. CNS
regimen involves potent intrathecal prophylactic chemotherapy that starts during the remission
induction phase of treatment [19]. The intrathecal chemotherapy can include methotrexate only or
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incorporate cytarabine and hydrocortisone in the intrathecal therapy with methotrexate which is
called the triple intrathecal therapy [20].
Table 1
Phases of ALL Treatment
Phase
Remission
Induction

Duration
4-6 weeks

Effect
Sets a
benchmark to
about 95% of all
pediatric patients
upon completion
and
improve eventfree survival
(EFS)

Drugs Involved
Corticosteroids, vincristine,
and asparaginase, in addition
to anthracyclines such as
doxorubicin or daunorubicin

References
[6, 11]

Consolidation

6-9 months

2-3 years

CNS Therapy

Throughout
the therapy
duration

Allogenic
hematopoietic
stem cell
transplant
(HSCT)

After
remission
induction
failure

Chemotherapeutic agents
such as cyclophosphamide,
cytarabine, thioguanine,
methotrexate, etoposide, and
thiopurine drugs such as
mercaptopurine
methotrexate and 6mercaptopurine
Potent intrathecal
prophylactic chemotherapy
using methotrexate only or
triple intrathecal therapy by
incorporating cytarabine and
hydrocortisone to
methotrexate,
cranial irradiation
Total body irradiation (TBI)
before stem cell transplant

[6]

Maintenance

eliminate
the
submicroscopic
residual disease
that exists after
complete
remission
Minimizes the
risk of relapse.
Less CNS
relapse
frequency

Increases
survival rates
and beneficial
for patients with
evidence of
higher risk of
relapse and
remission
induction failure

[16]
[19, 20]

[21]

Studies have reported no difference in outcomes of both therapy regimens, such as overall
survival and event-free survival. However, evidence shows that triple intrathecal therapy has
delivered less CNS relapse frequency. Chemotherapy that is composed of high-dose methotrexate,
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dexamethasone, cytarabine, and asparaginase is known to be CNS effective [20]. Peripheral
hyperleukocytosis is one of the risk factors of CNS disease development in ALL upon diagnosis
in addition to T-cell immunophenotype. Some CNS regimens can include additional cranial
irradiation if ALL patients are at increased risk for CNS infiltration. Cranial irradiation is known
to maximize the risk of neurocognitive deficits and secondary malignancies [19].
Another protocol that enhances survival rates is the allogeneic hematopoietic stem cell
transplant (HSCT) regardless of the stem cell source whether it is matched related, matched
unrelated, cord blood, or haploidentical donor. Allogenic HSCT is considered beneficial for
pediatric ALL patients with evidence of a higher risk of relapse and remission induction failure. It
is believed that exposure to total body irradiation (TBI) as a preparation phase for HSCT improves
patients’ outcomes after achieving a condition of MRD-negative disease [21].
Complications Associated with ALL Treatment
Although current approaches to the treatment of ALL have enhanced the event-free
survival rates among children to be more than 80% and 5-year survival rates to be more than 90%,
there is a higher risk for children to develop treatment-related toxicity and complications [1, 22,
23]. While the higher rates of survival reflect an increased response to chemotherapy regimens,
unfortunately, the toxicity of treatment can develop complications that can affect every organ in
the child’s body and even can cause death [24]. Chemotherapy regimens have the ability to cure
tumors whether they are in initially diagnosed or more advanced cases. Such treatment is crucial
to the survival of many ALL patients by effectively destroying malignant cells. However,
chemotherapy regimens do not differentiate between malignant cells and normal healthy cells in
different parts of the body including the hematopoietic tissue, gastrointestinal tract, and oral
mucosa [25]. Accordingly, a variety of complications are experienced at a very large scale in ALL
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pediatric patients due to treatment toxicity [22]. Some of these complications are addressed in this
thesis, and they include pulmonary embolism, concurrent diabetic ketoacidosis and pancreatitis,
cancer-related fatigue, steroid-induced glaucoma, osteonecrosis, tumor lysis syndrome, varicella‐
zoster virus infection, invasive fungal infections, and oral mucositis. Several studies have
investigated these complications as discussed below.
Pulmonary Embolism
One of the toxicities related to ALL treatment in children is a thromboembolism, which is
associated with pulmonary embolism. Pulmonary embolism is a very dangerous and fatal event
that can affect the sequence of ALL treatment. An observational study was conducted to
investigate the incidence of pulmonary embolism using a group of pediatric patients who were
treated by following the Nordic Society of Pediatric Hematology and Oncology (NOPHO)
ALL2008 protocol [24]. This study reported that the incidence of pulmonary embolism reached
its peak with infants less than 1-year-old and adolescents who were treated with asparaginase and
steroids. Asparaginase was found to cause a reduction in procoagulant, anticoagulant, and
fibrinolytic protein levels. Thus, increasing the risk of thrombosis. In addition to asparaginase,
factors related to thromboembolism and pulmonary embolism include obesity, T-cell leukemia,
and dexamethasone use in the induction phase of treatment. Patients who develop thromboembolic
events discontinue asparaginase treatment, and they are reimaged before resuming this treatment.
However, asparaginase treatment is resumed after the end of the thromboembolic events [24].
Concurrent Diabetic Ketoacidosis and Pancreatitis
When ALL adolescents are treated during the induction stage with L-asparaginase-based
chemotherapy, there is a possibility that an incidence of diabetic ketoacidosis with pancreatitis is
likely to occur. There is a 15% chance for chemotherapy treated ALL children to develop
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infections, pancreatitis, and hyperglycemia [26]. L-asparaginase was found to be an effective
addition in treatment that results in better clinical outcomes. However, some studies revealed
adverse events associated with L-asparaginase use in ALL treatment. These adverse events include
hypersensitivity reactions such as diabetic ketoacidosis and pancreatitis in addition to other
complications

such

as

hepatotoxicity,

intracranial

hemorrhage,

hyperglycemia,

and

hypersensitivity reactions among others [26].
Hyperglycemia is a consequence of using L-asparaginase- and prednisolone-based
treatment mainly with children > 10 years old. Hyperglycemia incidence due to the use of Lasparaginase was reported by one study to be approximately 9.7% [26]. Treatment of ALL in
children using L-asparaginase was found to hinder the production of insulin as a consequence of
its amino acid asparagine depletion effect. The precise pathogenesis of L-asparaginase that results
in complications is not known yet. However, its asparagine depletion effect is the consequence of
deamidation of asparagine to ammonia and aspartic acid or iso-aspartic acid which can reduce
protein synthesis in malignant lymphoblasts [22].
The presence of pancreatitis among pediatric ALL patients results in dysfunction of β cells
which is associated with a decline in insulin production from these cells in the pancreas. Moreover,
some metabolic abnormalities, such as hyperglycemia and diabetes mellitus are associated with
ALL patients with pancreatitis. It is documented that the incidence of pancreatitis developed due
to L-asparaginase was 2-18% with 8% of pediatric ALL patients who have developed pancreatitis
due to this treatment need to obtain insulin therapy. Also, it is reported that 0.75-2.3% of ALL
cases can develop diabetic ketoacidosis [26]. A study revealed that ALL patients developed
diabetic ketoacidosis in the induction phase after sixteen days from receiving the first dose of Lasparaginase.
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Figure 1
Grey Scale Ultrasound Image Showing Features of Acute Pancreatitis: Part of the pancreas appears slightly
bulky and enlarged. Adopted with permission from Jameel et al. BMC Pediatrics, 20(1), 228–228.
https://doi.org/10.1186/s12887-020-02136-3 (an open access article)

While diabetic ketoacidosis has short-term morbidity, it can cause permanent
consequences. However, the incidence of acute pancreatitis is 2% in children who developed
diabetic ketoacidosis [26]. Studies show that inflammation in the pancreas is associated with
pancreatic enzyme leakage [26]. Pancreatitis is confirmed if two of the three following principles
are attained: 1. Test of pancreatic amylase and lipase enzymes is ≥ 3 times the upper normal limit,
2. Imaging of the pancreas shows pancreatitis, 3. Patient suffers from abdominal pain [22]. A study
by Jameel et al. was conducted on a 14-year-old female with B-cell ALL. The girl received
vincristine, prednisolone, daunomycin, intrathecal methotrexate, and non-pegylated Lasparaginase in the induction phase of chemotherapy. After 20 days of therapy, a sonogram of the
abdomen revealed a bulky pancreas as shown in figure 1. It has been postulated that excessive
dosage of L-asparaginase and higher risk stratification associated with ALL can increase the risk
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for developing pancreatitis. Acute lymphoblastic leukemia patients who develop both pancreatitis
and diabetic ketoacidosis are significantly exposed to morbidity and mortality [26].
If glucose levels are acceptable in ALL patients with insulin treatment, asparaginase
therapy can be continued. Therefore, for ALL patients who receive L-asparaginase, frequent
follow-up and monitoring of blood glucose levels are crucial for detecting hyperglycemia which
can be an indication for potential pancreatitis as well. In addition, insulin therapy is recommended
for severe cases to avoid nonketotic hyperosmolar coma and enhance wound healing [26]. Due to
the importance of not interrupting or discontinuing the use of asparaginase treatment, it is
significant to identify any toxicities associated with this treatment. In the case of pancreatitis
associated with asparaginase treatment in ALL pediatric patients, a mild condition can be managed
by holding the asparaginase treatment for a while until all symptoms are diminished and normal
amylase levels are reached. However, asparaginase should be stopped if pancreatitis is acute or
hemorrhagic and resumed again once symptoms subside because premature discontinuation can
affect a patient’s survival [27].
Cancer-Related Fatigue
Cancer-related fatigue is a multidimensional complication of cancer treatment including
ALL treatment and is associated with impaired sleep-wake rhythms. Cancer-related fatigue is a
distressing uncomfortable condition that hinders children from properly function in school and
decreases their activity level. Its fundamental mechanism is not accurately perceived; however, a
biopsychosocial model that includes biological, medical, and behavioral factors can contribute to
this fatigue condition. Accordingly, evaluating the sleep-wake rhythm using actigraphy (ACT)
with some biopsychosocial factors can lead to an improvement in cancer-related fatigue in
pediatric ALL patients [28]. Although polysomnography (PSG) is the gold standard for sleep
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assessment, it is easier to use the non-invasive ACT assessment tool with children to record the
sleep-wake patterns [29]. Another factor for assessing circadian dysregulation is the production of
melatonin which is influenced by light. While the melatonin production in children is not affected
by ALL, other factors such as chemotherapy, toxicity due to therapy, and hospitalization could
jeopardize melatonin production through increasing light exposure. There is evidence that there is
an association between unstable and impaired sleep-wake rhythm and high levels of cancer-related
fatigue in ALL patients. Such evidence can assist in developing suitable interventions to improve
children’s sleep quality and hygiene to improve their health outcomes and reduce cancer-related
fatigue [28].
Steroid-Induced Glaucoma
Glaucoma is a chronic and escalating optic neuropathy that affects more than 60 million
patients worldwide. Glaucoma is considered one of the main causes of irreversible vision loss due
to its damaging effect on the optic nerve. Elevated intraocular pressure is the major risk factor for
developing glaucoma. In the first stages of glaucoma, the patient is asymptomatic with no clue that
the peripheral field of vision is affected. However, the patient becomes symptomatic with impaired
vision in the advanced stages when the central field of vision is affected. When intraocular pressure
is monitored and regulated, glaucoma can be controlled and curbed without reversing the impaired
vision [30].
While glaucoma mainly affects adults, steroid-induced glaucoma can affect any patient
receiving corticosteroids by any route regardless of age. The main concern with steroid-induced
glaucoma is the rise of intraocular pressure that can last for a few hours after steroid administration
or for many years with continuous steroid use [30]. It is reported that the response of intraocular
pressure to steroids is higher, more frequent, and severe in children [31]. Without adequate
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monitoring of elevated intraocular pressure with steroid administration, steroid-induced glaucoma
can be developed [30]. A study was conducted on a group of children between the ages of 4 and
15 years old who were receiving chemotherapy for ALL. Some of these children received only
doses of dexamethasone or prednisolone while the others were administered both medications
during the period of study. The mean value of the intraocular pressure was about 30 mmHg in 90%
of pediatric patients who were administered dexamethasone, while prednisolone did not raise the
intraocular pressure more than 15.5 mmHg. For those children who were under the age of 9 years
old, the mean intraocular pressure was significantly high (40.5 mmHg) compared to those who
were more than ten years old where the mean intraocular pressure was 23 mmHg [31].
Typically, young ALL children are unable to complain about symptoms associated with
high intraocular pressure such as headache, impaired vision, or photophobia. Therefore, it is crucial
to monitor children who are under steroid therapy, especially dexamethasone, for high intraocular
pressure even in the absence of accompanying symptoms. There is always a probability for ALL
pediatric patients of developing glaucoma with therapy containing corticosteroids [31]. In such
cases, topical anti-glaucoma medications are started with the patient such as brimonidine,
brinzolamide, and latanoprost with temporarily discontinuing steroids from the chemotherapy
regimen. Steroids are discontinued to reduce intraocular pressure and avoid optic nerve damage.
However, if the use of steroid therapy cannot be avoided, it is effective to closely monitor
intraocular pressure and intervene promptly whenever it is necessary since glaucoma can lead to
loss of vision that cannot be reversed [30].
Osteonecrosis
Osteonecrosis is one of the most occurring complications related to ALL treatment in
children that negatively impacts the quality of patients’ lives for many years. Osteonecrosis is a
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result of impaired vascular support in bone tissues leading to mechanical failure. Corticosteroid
treatment is believed to be associated with the etiology of osteonecrosis. However, some studies
reported that the combination of corticosteroids and other drugs of ALL chemotherapy regimen,
such as asparaginase and methotrexate, could contribute to the development of osteonecrosis [32].
Children who are aged ten or older are prone to osteonecrosis 10-20 times more than those children
under the age of 10 and more than adults. Gender and race pose another risk for developing
osteonecrosis. Female gender and Caucasian race are two more risk factors for children with ALL
to develop osteonecrosis. Moreover, osteonecrosis due to ALL treatment is mainly developed in
the lower extremities and shoulders as shown in figure 2 [33].
Some patients are symptomatic, and they constitute 1-18% of ALL patients with
osteonecrosis. Some patients are asymptomatic or have mild symptoms. However, others are
disabled due to experiencing severe pain from multiple affected joints. This pain can result from
osteoarthritis, bone marrow edema, subchondral collapse with cartilage delamination, and
microfracture associated with osteonecrosis. As with the case of glaucoma, the combination of
dexamethasone and asparaginase was found to be a higher risk factor for developing osteonecrosis.
If the ALL treatment is associated with musculoskeletal pain for more than a week, it is
recommended that the patient is assessed for osteonecrosis [33]. Effective decisions about
osteonecrosis treatment and surgical procedures with ALL patients is very complicated because it
involves other factors such as the chemotherapy phase and other health issues that should be taken
into consideration. These decisions must be compatible with pediatric ALL treatment, and they
need the collaboration of physicians from multiple disciplines such as orthopedic, oncology, and
anesthesiology [33].
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Figure 2
Osteonecrosis in the Hip: Difference between a normal hip joint & a necrotic hip joint. They were adopted
from the Mount Sinai website. adopted from Mount Sinai Website Osteonecrosis Information | Mount Sinai
- New York reference: C. Benjamin Ma, MD, Professor, Chief, Sports Medicine and Shoulder Service,
UCSF Department of Orthopaedic Surgery, San Francisco, CA. Also reviewed by David Zieve, MD, MHA,
Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

Treatment recommendations from previous clinical studies were based on idiopathic
osteonecrosis treatment with children or adults. It is not well documented how effective is the
combination of osteonecrosis surgical treatment and ALL treatment on the healing process of the
child’s bones. Also, invasive procedures are not the best decision for children who are exposed to
excessive infection and poor healing due to chemotherapy. Nonoperative treatment is basically
recommended for patients who are less than l0 years old or have smaller lesions. Larger lesions in
patients older than ten years old can be the source of pain and osteoarthritis and might require
operative treatment and total hip arthroplasty. Better outcomes are associated with early diagnosis
and intervention to avoid joint deformity. There is no reliable clinical data for the treatment of
pediatric ALL patients with osteonecrosis [33].
Tumor Lysis Syndrome
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The list of complications associated with chemotherapy and other ALL treatment drugs is
very long and complicated. Another ALL chemotherapy complication is tumor lysis syndrome,
which is a life-threatening metabolic abnormality. Tumor lysis syndrome is associated with high
morbidity and mortality. It is caused by enormous cytolysis that produces intracellular metabolites
such as protein products, potassium, phosphate, purine, and uric acid. The effluence of the
intracellular metabolites accumulates in the blood, cannot be renally excreted, and results in
abnormalities such as hypocalcemia, hyperuricemia, hyperphosphatemia, hyperkalemia, and acute
kidney injury [35].
Laboratory tumor lysis syndrome can be detected within 3-7 days after chemotherapy if
more than two of these abnormalities exist. Lab results confirming the presence of tumor lysis
syndrome show hypocalcemia with calcium level < 7 mg/dL, hyperuricemia with uric acid > 8
mg/dL, hyperphosphatemia with serum phosphate > 6.5 mg/dL, and hyperkalemia with potassium
> 6 mEq/L. However, clinical tumor lysis syndrome is detected when one abnormality exists. For
example, the patient experience features of acute kidney injury (serum creatinine exceeds the
normal upper limit by 1.5 times and the patient experiences oliguria for 6 hours), severe renal
impairment, features of leukostasis such as brain hypoxia, seizures, and intracranial bleeding,
cardiac arrhythmias, or death [35].
Figure 3 shows both the laboratory and clinical tumor lysis syndromes with a comparison
between the frequency of biochemical and renal abnormalities in both of them. The figure is one
of the outcomes of a study by Naeem et al. (2019) that used 57 pediatric ALL patients. In this
study, the most common abnormalities were found to be hyperphosphatemia and hyperuricemia in
both the laboratory and clinical tumor lysis syndromes. Whereas hypocalcemia and hyperkalemia
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were the least common, and acute kidney injury is found only in clinical tumor lysis syndrome
[35].
Figure 3
A Comparison Between the Frequency of Biochemical and Renal Abnormalities in lab and clinical tumor
lysis syndrome. Adopted with permission from Naeem et al., Pakistan Journal of Medical Sciences, 35(4),
899–904. https://doi.org/10.12669/pjms.35.4.715 (An open access article)

Tumor lysis syndrome can rarely develop spontaneously and if it occurs, serious clinical
outcomes will be experienced too [35, 36]. Many factors contribute to increasing the risk for tumor
lysis syndrome, such as the stage of ALL at diagnosis, the aggressiveness of the disease, the
chemotherapy protocol, the lactate dehydrogenase level, body sensitivity to chemotherapy, and
pre-existing conditions before ALL diagnosis. High-risk ALL patients have serum lactate
dehydrogenase level (LDH) ≥ 2 × upper level of normal (ULN) [36]. Tumor lysis syndrome
develops when chemotherapy incorporates prednisone, asparaginase, vincristine, and
daunorubicin. Since tumor lysis syndrome is an oncological emergency that should be handled
effectively, it is crucial to identify high-risk ALL patients undergoing chemotherapy early enough,
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provide them with prophylactic interventions, and monitor them continuously for complications
such as acute kidney injury, arrhythmia, and manifestations of the central nervous system. Early
intervention is a major factor in reducing the intensity and frequency of tumor lysis syndrome that
can result in more preferable outcomes [35].
Varicella‐Zoster Virus Infection
Varicella-zoster virus infection is an acute disease that affects children with ALL more
than in the general population of children. It may lead to complications specifically with pediatric
ALL patients who undergo chemotherapy [37]. In spite of the vaccines given to the general
population of children, prophylaxis with acyclovir or immunoglobulins presents a risk factor for
children who receive immunosuppression medications. Children with ALL are subject to immune
suppression, and they are more prone to develop varicella-zoster virus infection. Chemotherapy
administered to children has an impact on reducing the level of immunoglobulins, B-lymphocytes,
and T-lymphocytes [38].
The risk for developing varicella-zoster virus infection is even more when chemotherapy
is combined with steroids leading to more complications in children with ALL. It is recommended
that steroid therapy be postponed until the end of the incubation period of varicella-zoster virus
infection. On the other hand, steroid therapy cannot be delayed for patients receiving
chemotherapy in the induction period for its significance in this period. Most of the patients who
developed varicella-zoster virus infection were on aggressive chemotherapy and steroid therapy
and some developed lymphopenia associated with herpes zoster. Moreover, during the first two
years after diagnosis of ALL, 80% of pediatric patients are prone to develop Herpes zoster [39].
While chemotherapy was the main cause for developing varicella-zoster virus infection in ALL
patients, the type and dosage of steroid therapy were correlated with the intensity of this infection.
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Therefore, in the induction period, pediatric ALL patients should be administered varicella-zoster
immune globulin along with acyclovir directly after exposure prophylaxis [38].
Invasive Fungal Infections
Immunocompromised pediatric ALL patients are exposed to invasive fungal infections
which is the main cause of high morbidity and mortality. Invasive fungal infections are predicted
in pediatric ALL patients who are exposed to chemotherapy and prolonged corticosteroid therapy,
have neutropenia, or have undergone hematopoietic cell transplant [40]. Invasive fungal infections
are a consequence of opportunistic fungal pathogens that include fusariosis, aspergillosis,
candidiasis, cryptococcosis, trichosporonosis, and mucormycosis [41]. According to Wang et al.
(2019), complications experienced by pediatric ALL patients that are associated with fungal
infections were assessed in the United States. This assessment revealed that the incidence of
invasive fungal infections is maximized during the intensive induction and re-induction phases of
treatment. The degree of invasive fungal infections depends on the risk category and chemotherapy
and prophylaxis regimens and they ranged from 4% to 35% [40]. Patients with invasive fungal
infections can experience an incidence of drug resistance resulting in a higher mortality rate [41].
Oral Mucositis
Oral mucositis is the most significant oral complication and the most common associated
with chemotherapy regimens that lead to inflammation and ulceration of the oral mucosa. Clinical
manifestations of oral mucositis include erythematous and edematous mucosa and atrophy causing
much pain, discomfort while eating and drinking, dysphagia, and weakness [25]. Furthermore, oral
mucositis causes psychological distress and diminished functionality and quality of life. It is
significant to perform oral monitoring for patients during chemotherapy, especially when
methotrexate is involved in the treatment regimen. Such oral monitoring can prevent the
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treatment’s stomato toxic effect that causes oral lesions and decreases the quantity of saliva and
oral functions. After the initiation of chemotherapy by 5-7 days, the oral mucositis becomes visible
and continues through the treatment period showing mucosal changes, cellular desquamation, and
symptomatic ulcers [25].
A study by Ribeiro et al. (2017) was conducted on a group of children with ALL aged 018 years old. These children were monitored and assessed weekly for a period of 10 weeks. The
study reported that in the first six weeks of assessment, children who developed oral mucositis
experienced pain, impaired voice, and dysphasia. However, dysphagia associated with pain was
experienced after the 7th week. Starting from the 8th week, changes were apparent in oral tissues
and the tongue leading to difficulty eating and malnutrition in those patients and resulting in
comorbidities affecting their quality of life and survival [25].
Lips of the patients showed the presence of ulcerations in almost half the number of patients
and ulcerations were obvious in the labial mucosa from the 2nd week to the 10th week of treatment
[25]. These changes in the oral mucosa are evaluated using the Oral Assessment Guide (OAG), an
8-item scale: voice, swallowing, lips, tongue, saliva, mucous membrane (buccal mucosa, palate),
mucous membrane (labial mucosa), and gingiva [25]. The OAG scores each item as 1(normal), 2
(mild-to-moderate), and 3 (severe impairment) as illustrated in Table 2. Usually, chemotherapy is
stopped when oral lesions are present and are resumed after healing, a matter that negatively affects
the treatment process of the patient [25]. However, a study by Silva (2020) revealed that ALL
pediatric patients who received chemotherapy and were treated with either antimicrobial
photodynamic or photobiomodulation therapies had shown positive results in the reduction of pain
and time span of oral mucositis [42].
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Table 2
Evaluation for Oral Health of Patients Undergoing Chemotherapy Using OAG. Adopted from Ribeiro et
al., Int J Environ Res Public Health, 14(12), 1468. https://doi.org/10.3390/ijerph14121468 (an open access
article)

Item

1

Voice

Normal

Swallowing

Normal swallowing

Score
2
Deeper or raspy

3
Difficult talking or
painful speech
upon Unable to swallow

Some pain
swallowing
Lips
Smooth and moist
Dry or cracked
Tongue
Pink and moist and Coated or loss of
papillae present
papillae with a shiny
appearance with or
without redness
Saliva
Watery
Thick or ropy
Mucous Membrane
Pink and moist
Reddened or coated
(buccal
mucosa,
(increased whiteness)
palate)
without ulceration
Mucous Membrane
Pink and moist
Reddened or coated
(labial mucosa)
(increased whiteness)
without ulceration
Gingiva
Pink and stippled and Edematous with or
firm
without redness

Ulcerated bleeding
Blistered or cracked

Absent
Ulceration with
without bleeding
Ulceration with
without bleeding

or
or

Spontaneous bleeding
or bleeding with
pressure

Another study by Driehuis et al. (2020) reported that the use of leucovorin as a pretreatment
to starting the methotrexate could reduce the toxicity related to methotrexate and minimize the
proliferation of oral mucosa cells [42]. Other therapies, such as administering palifermin and
radiation therapy using low-level laser therapy were found effective in the management and
treatment of oral mucositis. Palifermin is a recombinant keratinocyte growth factor (KGF) used
for severe mucositis. Low-level laser therapy helps in fast healing and in reducing the incidence
and duration of severe oral mucositis [43].
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CHAPTER 3 CONCLUSION
Acute lymphoblastic leukemia affects a large number of children, and it is diagnosed when
lymphoblasts are present in bone marrow or peripheral blood. Treatment regimens of ALL are
determined mainly by risk-based stratification leading to the survival of a large number of pediatric
patients. High-risk cases demand aggressive and toxic treatments than those with standard-risks.
Though these aggressive regimens have better response rates, they accompany a variety of
complications including pulmonary embolism, osteonecrosis, tumor lysis syndrome, and many
such treatment emergent adverse events. Periodic follow-ups and being vigilant for some of these
expectant complications may negate the morbidity and mortality associated with these adverse
events in pediatric ALL patients.
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Acute lymphoblastic leukemia (ALL) is the most prevalent type of leukemia among
children. It is characterized by chromosomal and genetic variations and abnormalities occurring in
the leukemic cells. Prognosis predictors of ALL depend on risk-based stratification and the
reaction to the initial therapy. Current treatment regimens of ALL contribute to the survival of
approximately 80% of pediatric ALL patients with 90% 5-year event-free survival. Based on the
patient’s features impacting prognosis and risk of therapy failure, cases can be designated to
receive the adequate type of treatment regimens. The higher the risk, the more aggressive,
intensive, and toxic is the treatment regimen. Chemotherapy is the base of ALL treatment and it is
composed of 4 major phases, remission induction, consolidation, maintenance, and therapy
directed mainly to the central nervous system (CNS). There is a high risk for a multitude of
complications and medical problems associated with toxic chemotherapy regimens used with
pediatric ALL patients. Some of these complications are pulmonary embolism, concurrent diabetic
ketoacidosis and pancreatitis, cancer-related fatigue, steroid-induced glaucoma, osteonecrosis,
tumor lysis syndrome, varicella‐zoster virus infection, invasive fungal infections, and oral
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mucositis. However, early detection of these complications can contribute to a lower risk of
morbidity and mortality.
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